Literature DB >> 14504108

Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations.

Rajendra N Damle1, Franak M Batliwalla, Fabio Ghiotto, Angelo Valetto, Emilia Albesiano, Cristina Sison, Steven L Allen, Jonathan Kolitz, Vincent P Vinciguerra, Prasad Kudalkar, Tarun Wasil, Kanti R Rai, Manlio Ferrarini, Peter K Gregersen, Nicholas Chiorazzi.   

Abstract

Patients with B-cell chronic lymphocytic leukemia (B-CLL) segregate into subgroups with very different survival times. Because clinical observations suggest that leukemic cells accumulate at different rates, we measured telomere length and telomerase activity in B-CLL cells to distinguish differences in cellular replication. Our data indicate that the telomeres of B-CLL cells are shorter than telomeres of B cells from healthy subjects, indicating that the leukemic cells have a prolonged proliferative history. Leukemic cells of the immunoglobulin V gene mutation subgroups differ in telomere length and telomerase activity. B lymphocytes from the subgroup with poor outcome and with limited IgV gene mutations have uniformly shorter telomeres and more telomerase activity than those from the subgroup with better outcome and with considerable mutations. Differences in telomere length appear to largely reflect the proliferative histories of precursors of the leukemic cells, although differences in cell division, masked by the action of telomerase, cannot be excluded. These results may provide insight into the stages of maturation and the activation pathways of the cells that give rise to B-CLL. In addition, they reinforce the concept that B-CLL is not simply an accumulative disease of slowly dividing B lymphocytes but possibly one of B cells with extensive proliferative histories.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14504108     DOI: 10.1182/blood-2003-04-1345

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  37 in total

1.  Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes.

Authors:  Enrica Rampazzo; Laura Bonaldi; Livio Trentin; Carlo Visco; Sonia Keppel; Silvia Giunco; Federica Frezzato; Monica Facco; Elisabetta Novella; Ilaria Giaretta; Paola Del Bianco; Gianpietro Semenzato; Anita De Rossi
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

Review 2.  Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities.

Authors:  Nicholas Chiorazzi; Manlio Ferrarini
Journal:  Blood       Date:  2010-12-09       Impact factor: 22.113

Review 3.  Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia.

Authors:  Graham Packham; Freda K Stevenson
Journal:  Immunology       Date:  2005-04       Impact factor: 7.397

4.  The CD38 ectoenzyme family: advances in basic science and clinical practice.

Authors:  Fortunato Morabito; Rajendra N Damle; Silvia Deaglio; Michael Keating; Manlio Ferrarini; Nicholas Chiorazzi
Journal:  Mol Med       Date:  2006 Nov-Dec       Impact factor: 6.354

5.  CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells.

Authors:  Rajendra N Damle; Sonal Temburni; Carlo Calissano; Sophia Yancopoulos; Taraneh Banapour; Cristina Sison; Steven L Allen; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2007-08-07       Impact factor: 22.113

6.  Multiple productive immunoglobulin heavy chain gene rearrangements in chronic lymphocytic leukemia are mostly derived from independent clones.

Authors:  Karla Plevova; Hana Skuhrova Francova; Katerina Burckova; Yvona Brychtova; Michael Doubek; Sarka Pavlova; Jitka Malcikova; Jiri Mayer; Boris Tichy; Sarka Pospisilova
Journal:  Haematologica       Date:  2013-09-13       Impact factor: 9.941

7.  Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP.

Authors:  Kumudha Balakrishnan; Christine M Stellrecht; Davide Genini; Mary Ayres; William G Wierda; Michael J Keating; Lorenzo M Leoni; Varsha Gandhi
Journal:  Blood       Date:  2005-02-17       Impact factor: 22.113

Review 8.  From pathogenesis to treatment of chronic lymphocytic leukaemia.

Authors:  Thorsten Zenz; Daniel Mertens; Ralf Küppers; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Nat Rev Cancer       Date:  2009-12-03       Impact factor: 60.716

9.  In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia.

Authors:  Carlo Calissano; Rajendra N Damle; Gregory Hayes; Elizabeth J Murphy; Marc K Hellerstein; Carol Moreno; Cristina Sison; Matthew S Kaufman; Jonathan E Kolitz; Steven L Allen; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2009-09-29       Impact factor: 22.113

Review 10.  Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance.

Authors:  Michele Dal-Bo; Francesco Bertoni; Francesco Forconi; Antonella Zucchetto; Riccardo Bomben; Roberto Marasca; Silvia Deaglio; Luca Laurenti; Dimitar G Efremov; Gianluca Gaidano; Giovanni Del Poeta; Valter Gattei
Journal:  J Transl Med       Date:  2009-08-28       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.